维基百科

利生奇珠单抗

化合物

利生奇珠单抗（英语：Risankizumab），商品名为喜开悦（英语：Skyrizi）是一种皮下注射的人源单克隆抗体，用于治疗斑块状银屑病、干癣性关节炎、克隆氏症和溃疡性结肠炎[9]。它可以结合并阻断介白素23A（英语：Interleukin 23 subunit alpha）（IL-23A）[9] [10]。

利生奇珠单抗
单克隆抗体
种类完整抗体
目标interleukin 23A
临床资料
读音/ˌrɪsənˈkɪzʊmæb/
RIS-ən-KIZ-uu-mab
商品名（英语：Drug nomenclature）Skyrizi
其他名称BI-655066、ABBV-066、risankizumab-rzaa、瑞沙珠单抗
AHFS/Drugs.comMonograph
MedlinePlusa619035
核准状况
怀孕分级
给药途径皮下注射
ATC码
法律规范状态
法律规范
识别信息
CAS号1612838-76-2
PubChem SID
IUPHAR/BPS
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
化学信息
化学式C6476H9992N1720O2016S44
摩尔质量145,611.84 g·mol−1

最常见的副作用包括上呼吸道感染（鼻咽感染）[9]。

利生奇珠单抗于2019年在美国取得医疗使用许可[11] [12]，此外全球包括欧盟[9]、加拿大[3]、日本[8] [13]和台湾皆可获得医疗使用许可。

参考文献

编辑
  1. ^ Risankizumab (Skyrizi) Use During Pregnancy. Drugs.com. 15 July 2019 [23 September 2020]. 
  2. ^ Skyrizi (Abbvie Pty Ltd). Therapeutic Goods Administration (TGA). 11 November 2022 [9 April 2023]. 
  3. ^ 3.0 3.1 Skyrizi Product information. Health Canada. 25 April 2012 [29 May 2022]. 
  4. ^ Summary Basis of Decision (SBD) for Skyrizi. Health Canada. 23 October 2014 [29 May 2022]. 
  5. ^ Skyrizi 75 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC). (emc). [23 September 2020]. 
  6. ^ Skyrizi- risankizumab-rzaa kit. DailyMed. 18 June 2024 [2 November 2024]. 
  7. ^ Skyrizi EPAR. European Medicines Agency (EMA). 27 February 2019 [23 September 2020].  Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  8. ^ 8.0 8.1 AbbVie Expands Immunology Portfolio in the U.S. with FDA Approval of Skyrizi (risankizumab-rzaa) for Moderate to Severe Plaque Psoriasis. AbbVie (新闻稿). 23 April 2019 [9 August 2023]. 
  9. ^ 9.0 9.1 9.2 9.3 Skyrizi EPAR. European Medicines Agency (EMA). 27 February 2019 [23 September 2020]. 
  10. ^ Singh S, Kroe-Barrett RR, Canada KA, Zhu X, Sepulveda E, Wu H, et al. Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody. mAbs. July–August 2015, 7 (4): 778–791. PMC 4622456  . PMID 25905918. doi:10.1080/19420862.2015.1032491. 
  11. ^ Risankizumab-rzaa Monograph for Professionals. Drugs.com. [18 October 2021]. （原始内容存档于28 September 2021） （英语）. 
  12. ^ Skyrizi. [18 October 2021]. （原始内容存档于25 October 2020）. 
  13. ^ Japan Approves Risankizumab for Psoriasis & Psoriatic Arthritis. The Rheumatologist. 15 April 2019. 

外部连节

编辑
  • Clinical trial number NCT02684370 for "BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis" at ClinicalTrials.gov
  • Clinical trial number NCT02684357 for "BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis" at ClinicalTrials.gov
  • Clinical trial number NCT02672852 for "BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment" at ClinicalTrials.gov
  • Clinical trial number NCT02694523 for "BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis" at ClinicalTrials.gov
  • Clinical trial number NCT02054481 for "BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab" at ClinicalTrials.gov
检索自“https://zh.wikipedia.org/w/index.php?title=利生奇珠单抗&oldid=84864282”